ResMed Inc.

Welcome to the Q1 Fiscal Year 2020 ResMed Inc. earnings conference call. My name is Chris and I'll be your operator for today's call. At this time all participants are in a listen-only mode. Later we will conduct a question and answer session. Please note that this conference is being recorded. I will now turn the call over to Amy Wakeham, Vice President Investor Relations and Corporate Communications. Amy, you may begin.

Great. Thank you, Chris. Good afternoon and good morning, everyone. Thanks for joining us. Welcome to ResMed's first quarter fiscal year 2020 earnings call. This call is being webcast live and the replay along with a copy of the earnings press release and our updated investor presentation will be available on the investor relations section of our corporate website later today. Joining me on the call today to discuss our quarterly results are CEO Mick Farrell and CFO Brett Sandorcock. Other members of management will be available during the Q&A portion of the call. During our call we will discuss several non-GAAP measures. For reconciliation of the non-GAAP measures, please review the notes to today's earnings release. As a reminder, our discussion today may include forward-looking statements including but not limited to expectations about our future performance. We believe these statements are based on reasonable assumptions. However, our actual results may differ. You are encouraged to review our SEC filings for a discussion of the risk factors that could cause our actual results to differ materially from any forward-looking statements made today. With that, I'd now like to turn the call over to Mick.

Thanks, Amy, and thank you to all of our shareholders for joining us today as we review the results for ResMed's first quarter of fiscal year 2020. On today's call, I will discuss our long-term strategy. I'll then review top-level financial results, some business highlights from the quarter, and a few key milestones. Then I'll hand the call over to Brett, who will walk you through our financials in further detail. We have started fiscal year 2020 right where we left off with 2019. Our team achieved another quarter of balanced growth across the portfolio, driven by continued strong performance in the MAS category. We are taking share with recent new product introductions, and our solutions are enabling increased therapy adherence as well as expansion of resupply programs to those who need it. Our dedicated team of more than 7,500 ResMedians around the world have again delivered strong results. As the world's leading software-driven medical device company, we continue to use technology to advance our leadership position. We have sold more than ,100,000 cloud-connectable medical devices into the market, and our AirView cloud-based ecosystem manages more than 11 million patient accounts. In the last 12 months, we changed over 15 million lives by providing a person with a ResMed device or a complete mask system to help them breathe better and live better lives. In addition, our Bright Tree and Matrix Care branded -of-hospital software systems are helping to manage 93 million more people. So during the last 12 months, we improved more than 108 million lives with ResMed products, services and software solutions. We are well on our way to the ambitious goal to improve 250 million lives in 2025. Our connected solutions are providing us with valuable access to de-identified therapy data that we are using to derive actionable insights to benefit patients, physicians and providers, as well as to inform future innovation in products and software. These data sets are growing exponentially, and we now have 5 billion nights of medical sleep and respiratory care data in the cloud. Our relentless focus on product and software innovation continues to set us apart from our competition. We remain laser-focused on growth in our core market of sleep apnea, as well as in our adjacent respiratory medical markets of chronic obstructive pulmonary disease, as well as asthma. Our expanded focus to now grow outside the hospital's software solutions allows us to help customers create efficiencies, to take costs out of the healthcare system and to improve the quality of care across home medical equipment, home health, hospice, skilled nursing facilities, life plan communities and beyond. We believe the future of healthcare is outside the hospital. That's where ResMed competes today, that's where we are winning today, and that's where we will continue to win in the future as we provide market-leading value to customers. Let's now briefly review our top-level financial results for the quarter. We achieved another quarter of double-digit revenue growth, up 17% in constant currency across the portfolio. This growth was well-balanced across domestic US and global product sales, as well as balanced across our software as a service businesses. We continued to deliver operating leverage in the quarter, leading to a non-GAAP operating profit growth of 22% -over-year, and non-GAAP diluted earnings per share of 93 cents. Turning to a brief discussion of our sleep apnea and respiratory care businesses, in the devices category, we delivered a good quarter. We achieved -over-year constant currency device growth of 6% globally, to border by very strong 8% device growth in the United States, Canada and Latin America geographies. We achieved 4% constant currency growth of devices in combined Europe, Asia and rest of the world. We achieved excellent device growth in the UK, Switzerland and across our Nordics countries. As discussed over the last few quarters, we experienced a continued headwind during the quarter for device growth in France as a result of digital health-related fleet upgrades. We expect that headwind to ease by the end of this fiscal year and then return to market device growth in France. It is great to see a steady flow of our digital health solutions into different European countries and to see positive constant currency device growth across the continent this quarter. The growth in the masks and accessories category of our business was incredibly strong during the quarter. We were up 19% in constant currency globally. This is well ahead of market growth rates, indicating we gained significant market share during the quarter. The reason that we continue to take share around the world is that we make the smallest, the quietest and the most comfortable masks available in the market. Our flagship masks, the AirFit F20 and the AirFit N20, continue their growth across global markets. The success of these flagship masks was augmented during the quarter by good uptake of our recent mask launches. To recap those launches, we have now launched four new masks during the last 12 months. The F30, the N30i and the P30i. And just this week, actually on Monday, our newest innovation was launched, the N30. We have the right mask for every patient, every time. And the N30 adds innovative dimensions to this portfolio. The N30 is a world first, tube down, nasal cradle CPAP mask in a new product subcategory that we are calling the minimalist category. The N30 is our smallest, our lightest mask ever and our quietest nasal mask ever. I personally think this new N30 is another winner from our amazing research and development engineers. Watch this space as it gets into the hands of our market leading marketing and sales teams. Our mask portfolio overall is positioned to offer world leading options for physicians to prescribe, for home care providers to fit in a first time setup, and most especially for the needs of the ultimate customer, the person who suffocates every night with sleep apnea. We remain focused on driving innovation to meet all underserved customer needs. The bottom line is that our new masks have a lot of runway ahead. Unfortunately, they don't let me talk about ResMed's future product pipeline, so I won't. Our success comes as health care providers, physicians and patients around the world continue to vote with their wallets and choose ResMed products, not just for the innovative design and high quality of our devices and masks, but also for the sustainable value proposition of the digital health solutions that we offer. Our digital -to-end solutions combined with available 100% cloud connectivity, as well as information provided to patients on their own smartphones, through apps like MyAir and apps like Propeller, are all leading to significant improvements in lowering cost, in improving health outcomes and improving quality of life for patients around the world. Through digital health technology, we are driving patient engagement so that people can enjoy the benefits of the best therapy available. In parallel, we are also ensuring that the cost of chronic disease can be better managed by physicians, health care providers, payers and governments. There's still a long way to go. Our research that was just published by the Lancet Respiratory Medicine Journal in July shows that there are over 936 million sleep apnea sufferers worldwide, while only around 20 million or so are being treated today. We keep forging ahead, investing in our own research and development to drive further innovation and advancement, as well as by working with partners. On the partnership front, our joint venture with Verily is working on software solutions to help identify and engage and better manage more people with sleep apnea. It is very early days on in this JV, but our philosophy is that the more a person knows about how much they suffocate every night and the consequences of that suffocation on their own personal health care outcomes, the more likely they will seek solutions. Over time, we know this partnership will drive incremental growth in our core sleep apnea business, while allowing ResMed to participate in a broader chronic disease management ecosystem, covering not just sleep apnea, but also cardiovascular disease, diabetes, COPD and beyond. These chronic disease management platforms will include clinical care, as well as wellness improvements in nutrition, in cardiovascular exercise and in mental health. Let's now turn to our second vector of growth here at ResMed, our business in respiratory care. There are nearly 400 million people worldwide suffering from chronic obstructive pulmonary disease or COPD. We don't believe they are well served by healthcare systems today. We see the opportunity to better manage COPD through the use of technology with digital -to-end solutions that can help patients as they progress with this chronic disease, including how patients are communicated to, how patients are encouraged in their medical care and how patients are looked after as individual persons. We're advancing our respiratory care strategy in multiple ways. Earlier this summer, we introduced a number of enhancements to AirView, our cloud-based patient management platform. We are making management of ventilation patients much simpler and much more useful for home medical equipment providers. Physicians and HMEs can now look deep into therapy data to see key performance indicators such as pulse rate, inspiratory time, maximum airflow and even a patient's rapid shallow breathing index or RSBI. All these data are now available within our digital healthcare ecosystem with the -to-use AirView platform. Our goal is to help create a frictionless experience when managing COPD patients with ResMed's solutions. Our team at Propeller also continues to grow their business as we move from pilot trials to commercial partnerships with leading respiratory pharmaceutical companies. The team was recently at the European Respiratory Society Annual Congress in Madrid. It was great to see Propeller represented at multiple pharma booths, including live demonstrations of Propeller solutions for physicians. Propeller was also featured in several scientific presentations during ERS, including the public announcement of a new large COPD outcomes trial that's sponsored by Novartis. The trial will compare Propeller plus COPD standard of care to COPD standard of care alone. The trial has already begun enrolling patients during this quarter. As we outlined when we acquired Propeller in January, the digital health opportunity with respiratory medicine adherence will take time to build into critical mass. This quarter we passed a significant milestone with more than 100,000 people enrolled into the Propeller ecosystem. Let's be clear, we are still in the early days of market development here. The analogy is that we are now just lacing our shoes for the digital health ultramarathon in both COPD and in asthma. So there's lots of terrain ahead. The evolution that we have made in our respiratory care business has set ResMed up to become the global leader in digital health for COPD. From stage 1 and stage 2 COPD with Propeller's pharmaceutical adherence solutions to stage 3 and stage 4 COPD with portable oxygen concentrators as well as our cloud-connected non-invasive ventilation solutions. Let's now turn to our third vector of growth, our software as a service business. We continue to integrate and optimize the SAS portfolio for long-term growth. Our competitive advantage derives from our leadership position in SAS solutions for home medical equipment, for skilled nursing facilities, for home health, hospice, life plan communities and home care services. ResMed is the best strategic player competing in these verticals and we have the expertise running global digital health systems at scale to be able to succeed in the future. Our SAS portfolio continues its growth trajectory this quarter with revenue up 83% year on year during the quarter. Clearly growth in this first quarter was accelerated leveraging our matrix care acquisition in November of 2018. We will lap that acquisition during this current second quarter. We estimate that the underlying market growth of the blended portfolio of seven -of-hospital SAS verticals that we serve is in the high single digits. Leaving out the matrix care acquisition, we grew right in line with the market in Q1. We have set up an execution plan to continue to innovate and to continue to launch market-leading upgrades combined with new capabilities that will allow us to gain market share in our SAS verticals and participate in the fastest growing ones so that we can beat market growth. We plan to exit fiscal 2020 with solid double-digit growth in our SAS business segment. One example of the progress that we're making in our SAS portfolio is the recent announcement of our collaboration with Cerner as their new preferred provider for home health and hospice software. This agreement validates ResMed as an industry-leading provider of digital health solutions for -of-hospital healthcare. Our matrix care managed offering for home health and hospice customers includes the best of breed capabilities from both the matrix care technology and from the Bright Tree technology. This agreement ensures our home health and hospice solution is available to all of Cerner's large customer base. The net result is growth opportunities for both Cerner and matrix care sales teams. In fact, at the recent Cerner Healthcare Conference, a major healthcare system with a very large home health business was introduced to the ResMed solution and they are quickly moving towards a contract with our matrix care team. It is clearly early days as the ink dries on the Cerner contract, but the bottom line is we are excited to drive growth from this partnership and to leverage interoperability to provide value for all of our customers. In summary, for the SAS business, we have the vision to transform and significantly improve -of-hospital healthcare. We are helping people stay out of the hospital and in the care setting of their choice with lower costs and a higher quality of life for the person. The best place that people often choose is almost always their own home. Aging in place is a trend that is growing not just in the US but globally and we plan to enable and leverage that positive change. We think that's an important part of the future of healthcare. Before I turn the call over to Brett, let me close with this. We have had a great start to the new fiscal year and we are well positioned to grow throughout fiscal year 2020 and beyond. We have positioned ResMed for the long term as the global leader in digital health, driving both top line and bottom line growth as well as executing on our strategy to improve 250 million lives in healthcare that's delivered outside the hospital in 2025. We are focused on our triple aim, to slow chronic disease progression, to reduce overall healthcare system costs and to improve outcomes and quality of life for the ultimate customer, the person who simply wants to sleep well, to breathe well and to live a better life well away from that hospital. With that I'll turn the call over to Brett in Sydney for his remarks and then we'll open up for Q&A. Brett, over to you in Sydney.

Great, thanks Mitt. In my remarks today I will provide an overview of our results for the first quarter of fiscal year 2020. As Mick noted we had a strong quarter. Group revenue for the September quarter was $681 million, an increase of 16% over the prior year quarter. In constant currency terms revenue increased by 17%. Excluding revenue from acquisitions, group revenue increased by 11% on a constant currency basis. Taking a closer look at our geographic distribution and excluding revenue from our software as service business, our sales in US, Canada and Latin American countries were $370 million, an increase of 13% over the prior year quarter. Sales in Europe, Asia and other markets totaled $224 million, an increase of 4% over the prior year quarter. However, in constant currency terms sales in combined Europe, Asia and other markets increased by 8% over the prior year quarter. Breaking out revenue between product segments, US, Canada and Latin America device sales were $187 million, an increase of 8% over the prior year quarter. Masks and other sales were $183 million, an increase of 19% over the prior year quarter. For revenue in Europe, Asia and other markets device sales were $152 million, which is consistent with the prior year quarter, but in constant currency terms a 4% increase. Masks and other sales in Europe, Asia and other markets were $72 million, an increase of 15% over the prior year quarter, or in constant currency terms a 19% increase. Globally, in constant currency terms device sales increased by 6% while masks and other sales increased by 19% over the prior year quarter. Software as a service revenue for the first quarter was $87 million, an increase of 83% over the prior year quarter. During the rest of my commentary today I will be referring to non-GAAP numbers. The non-GAAP measures adjust the impact of amortisation of acquired intangibles and a purchase accounting fair value adjustment to matrix care deferred revenue. The prior year comparable excludes amortisation of acquired intangibles. We have provided a full reconciliation of the non-GAAP to GAAP numbers in our first quarter earnings press release. Our gross margin for the September quarter was .5% compared to .3% in the same quarter last year and .3% in Q4 FY19. Compared to the prior year, our gross margin increased by 120 basis points. This was predominantly attributable to manufacturing and procurement efficiencies, the matrix care acquisition and favourable product mix. Moving on to operating expenses. Our SG&A expenses for the first quarter were $167 million, an increase of 14% over the prior year quarter. In constant currency terms, SG&A expenses increased by 16%. Excluding acquisitions, SG&A expenses increased by 6% on a constant currency basis. SG&A expenses as a percentage of revenue improved to .6% compared to 25% that we reported in the prior year quarter. Looking forward, subject to currency movements and taking into account recent acquisitions, we expect SG&A as a percentage of revenue to be in the range of 23% to 24% for the remaining three quarters of fiscal year 2020. R&D expenses for the quarter were $48 million, an increase of 24% over the prior year quarter, or on a constant currency basis, an increase of 27%. Excluding acquisitions, R&D expenses increased by 2% on a constant currency basis. R&D expenses as a percentage of revenue was .1% compared to .6% in the prior year. Looking forward, subject to currency movements, we expect R&D expenses as a percentage of revenue to be in the range of 7% to 8% for the balance of fiscal year 2020. Amortisation of acquired intangibles was $18.5 million for the quarter, an increase of 44% over the prior year quarter, reflecting the impact from our recent acquisitions. Stock-based compensation expense for the quarter was $13.3 million. Nongap operating profits for the quarter was $191 million, an increase of 22% over the prior year quarter, while Nongap net income for the quarter was $135 million, an increase of 16% over the prior year quarter. Nongap diluted earnings per share for the quarter were $0.93, an increase of 16% over prior year quarter, while gap diluted earnings per share for the quarter were 83 cents. On a gap basis, our effective tax rate for the September quarter was 20.2%, while on a non-gap basis, our effective tax rate for the quarter was 20.6%. Looking forward, we estimate our effective tax rate for the full fiscal year 2020 will be in the range of 19 to 21%. Cash flow from operations for the first quarter was $162 million, reflecting robust underlying earnings. Capital expenditure for the quarter was $22.7 million. Increase in amortisation for the September quarter totalled $38 million. And during the quarter, we paid dividends of $56.1 million. We recorded equity losses of $6.8 million in our income statement in the September quarter associated with our Verily Joint Venture. We expect to record approximately $7 million of equity losses each quarter in fiscal year 2020 associated with the Joint Venture operations. Our Board of Directors today declared a quarterly dividend of $0.39 per share. During the quarter, we repaid $49 million of our outstanding debt. At September 30, we had $1.2 billion in gross debt and $1 billion in net debt. Our balance sheet remained strong with modest debt levels. Finally, to recap, our top line revenue was strong this quarter with growth across all major categories. Growth margin expanded and our operating costs remained well controlled. As a result, we're continuing to drive operating leverage with Q1 non-GAAP operating profit up 22% year on year. We are focused on driving operating results, integrating our SAS acquisitions and ensuring we continue to invest in our strategic long-term opportunities. And with that, I'll hand the call back to Amy.

Great. Thanks, Brett. We're now going to turn the call over to the Q&A portion. I'd like to remind everyone to please limit yourself to one question. If you have additional questions, please do feel free to return to the call queue. Chris, we're now ready for the Q&A portion of the call.

Thank you. We will now begin the question and answer session. If you have a question, please press star and then one on your touchstone phone. If you wish to be removed from the queue, please press the pound sign or the hash key. If you're using a speakerphone, you may need to pick up the headset first before pressing the numbers. We do ask that you please limit yourself to one question. Once again, if you have a question, that is star and then one on your touchstone phone. Our first question comes from Greta O'Jenner with Credit Suisse. Your line is open.

Thanks. Good morning. So just firstly, just on the US device growth continues to be very strong. Just wondering what would be the growth in kind of new patient setups in the quarter? Give us some detail on that.

Yeah, thanks for the question, Greta. So we don't actually have full visibility even to the number, right? We sell to, in the US, to home medical equipment companies that then sell to patients that are renewing in their five-year renewal or to new patients. We don't have full visibility into that.

But it

is interesting with a reasonably sized patient pool in the United States. It would be a good double-digit percentage or so of those that will be replenishment devices. But the 8% growth, I think, is really ahead of market. We think the market growth is in the sort of mid-single digits. And so to be at 8% growth in the US shows that we were taking some share due to the value of AirSolutions, AirView, and MyAir, and all the sort of digital health solutions that are there.

Thank you.

Thanks, Greta.

Your next question is from Steve Wein with Evans. Your line is open.

Yeah. Hi, guys. Just a question also on the devices. There seems to be, certainly amongst the DME land, a bit of a rush on COPD codes and the setting up of patients with ventilators. Just wondering if you're seeing any benefit from that, particularly amongst your Astril, or your ventilator range, in particular the Astril.

Steve, thanks for the question. We actually saw really solid growth in the core sleep business, as a sizeable chunk of that 8% growth in the US. Astril tends to be more of a player. Ventilation in general tends to be more of a player in Europe. And so some of that sort of 4% constant currency growth in Europe, Asia, and the rest of the world will have been driven by the Astril and some sort of much smaller element of the 8% US growth. But one thing that we've been really strong with our DME customers is to make sure that the right device goes on the right patient at the right time. And when you look at COPD, there are lots of solutions from our AirCurve S, our AirCurve ST, as well as non-invasive ventilation, as well as even our Stellar product in non-invasive ventilation, all the way through to our Astril product, which is really a life support ventilator and should be used in very severe COPD and in life support needs. And so, yeah, it really wasn't a huge contributor in the US this quarter, probably slightly more significant in Europe. But it's really good solid balance growth, if you like, from our sleep apnea side, with some additions from respiratory care is how I'd position it.

Great, thanks very much. Thanks, Dave.

Your next question comes from Margaret Kazur with William Blair. Your line is open.

Hey, good afternoon and good afternoon to most people. Good morning for others. But thanks for taking the question. Just kind of a big picture. I know some people are going to focus on the device sleep apnea growth, but in all, you guys ended up delivering 11% top line growth, excluding acquisitions, and that's above market in almost every category, and even as you're seeing a head win in France. So I guess looking out, whether it's this year or the next couple years, what prohibits you guys from continuing that double digit top line growth rate and what could drive it higher or lower from today's level?

Thanks. Thanks for the question, Margaret. Certainly we did have a very good quarter here in Q1, and as you said, we grew sort of 11% constant currency globally in our sleep and respiratory care combined businesses. You know, if you think about the global growth, and we have enough data now to know that the growth really is in that mid to high single digits. So devices growing in the mid single digits and masks growing in the high single digits. Clearly we did take share in Q1, and a lot of that is driven by the digital health technology on the flow generator side to have some of the share taking on the device side, and then the new product introductions that I detailed in the prepared remarks, four new masks, in addition to two strong flagship masks there. So NPI has been an incredible contributor to us. If you think through the year ahead, even during this quarter that we're currently in, the second quarter, we're going to lap one of those four product launches on the mask side, and we'll continue to lap those during the quarter. So look, I'm always very excited about our innovation, the smallest, the quietest, the most comfortable, the most connected, and I think that innovation drives. But you can't outgrow market forever, right? You've got to then focus on getting more patients into the funnel, which is our whole identifying gauge and enroll people in. So I think it was a fantastic Q1, but as we look through the fiscal year, we think we can meet or beat market growth, but you're not going to beat it every single time.

Great, thank you guys. Thanks,

Margaret.

Your next question is from David Lowe with JP Morgan. Your line is open.

Thanks very much. Mick, during the period, we heard, we saw from your competitor Phillips that they had issues with their connected care business. They talked about tariffs, etc. I'm just wondering, sort of market landscape in the US, whether you saw any disruption from that? Do you think some of the, that ResMed may have been a beneficiary of the issues that they were working through?

Yeah, I'll hand that,

good question, David. I'll hand that to Rob Douglas, our COR. Sure, David. Just generally on the tariffs issue, just to reiterate, as we've said before, the way our whole supply chain is configured, we're not really affected by the specific tariffs. We export very little into China from the US and very little from China to the US. Our supply chain is more Southeast Asian focus and we've got a great team in China doing local products for China, so that's pretty solid. Our Airview solutions, on the other hand, mostly by the way developed by teams all around the world, but really a strong product offering continues to deliver superior value to our customers and we think, you know, with day in and day out, we'll fight competition with those products and believe that we've got a better proposition to offer. So we, from our perspective, we didn't see any particular competitive issues that were sort of changing the normal competitive dynamics. We do have to sell and execute well and our teams have been doing that.

Great, right, thanks very much. Thanks, David.

Our next question is from Andrew Goodsall with MST Marklee. Your line is open.

Thanks very much, guys. Perhaps just thinking forward into competitive bidding and, you know, I guess, you know, the bids are in, so, you know, I guess by next summer we've got a sense of where the clearing prices land. I'm just wondering whether there's any preliminary comments you've got in your thoughts there or any preliminary actions you're taking, I guess, to prepare for competitive bidding and, you know, whether that involves new product launches or anything, you know, just any preliminary you're sort of doing or preparatory actions.

Yeah, thanks for the question, Andrew. I'll hand that to David Pandavas.

Thanks, Andrew. The, obviously, we spent a lot of time along with others in the industry trying to educate, you know, the market participants so they would be able to bid effectively and bid smartly given the new rules. We remain encouraged with the changes that were put in place principally that clearing price is what's going to drive reimbursement as opposed to the median price under the old regime and some of the other changes that were made including requiring bonds to bid in particular areas. We're hoping that that together with the education that the industry did will lead to smart bids and that'll lead to a fairer, more realistic reimbursement. We obviously didn't participate in the bidding process and haven't had direct conversations with customers about what they bid, so it's all conjecture at this point as to where the ultimate reimbursement will land, but no matter where it is, whether it's a private pay reimbursement change or a Medicare US change or something elsewhere in the world, you know, we're continually working with our customers to help them be more efficient, help them take advantage of the opportunities that present themselves and to, you know, enable them to better serve patients under whatever the reimbursement schemes are. So we'll definitely continue to do that and watch where the US Medicare landscape evolves, but at the moment that's still, you know, a year and a bit away. So we'll just keep doing what we're doing and obviously focus on it when the time comes.

Thank you. Thanks, Rich. Your next question is from Ian Harrison with Bank of America, Merrill Lynch. Your line is open.

Good morning, gentlemen. Thank you for taking my question. Solid mask growth outside of America, and I just wanted to understand, you've had one of your competitors launch a new full face mask outside of America. Have you seen any difference in your full face mask sales outside of the US versus within the US, and how are you positioning yourself now that they've got FDA approval to launch within the US?

Yeah, so thanks for the question, Leanne. And, you know, look, we have multiple competitors in the 120 countries we sell into, and we expect new product introduction from our competitors on a regular basis. Yeah, as you noted, during the quarter we had 19% constant currency growth in US, Canada, Latin America. We also had 19% constant currency growth of masks in Europe, Asia, and rest of the world, where some of those masks and new launches have already been in play during the quarter. So I think we've, you know, I know we've got the most robust sleep apnea mask portfolio on the planet versus our competitors in all 120 countries that we participate in, but there's no arrogance or hubris here. Our team of R&D engineers are furiously working, not only on a technology to address underserved needs, but to think differently about how to, you know, really achieve that ultimate goal, which is sort of, you know, the silent CPAP and the invisible mask. And if you look at the N30 that we just launched, this minimalist category mask, it's about as close to an invisible mask as you can get. It is small, it is quiet, it is comfortable. So, look, I love innovation coming to the market from our competitors and from us, because it keeps us all honest. But during the quarter, we performed very well versus all the NPI from our competitors with our own NPI. And I expect us to be able to do that into the future. And, you know, competition is just a healthy part of making sure that tens of millions of people get the breathing they need.

Thank you.

Your next question comes from John Teakinbell with Citi. Your line is open.

Hi John, good morning. Thanks for the question for Brett. Just to deconstruct that gross margin expansion a little bit. I think previously you've given us the fear for what was from the matrix care. But can you just maybe elaborate a bit more in terms of strong mass growth, higher margin that will have impacted and also whether there's a more benign pricing environment in the US which is helping as well?

Yeah, hi John, it's Brett. I mean, I think it's all of those things that probably the pricing environment is relatively benign at the moment. So impacts there are pretty modest. In terms of acquisitions, that contributed around 50 basis points. So if you think about that, still a really strong, let's call it organic, expansion of the margin, which is really good. That's really around the manufacturing and procurement efficiencies. And then clearly some product and expense there, as you saw the outperformance in the mass growth. So a combination of all those factors, I think, led to that expansion. Okay,

thanks Brett.

Your next question comes from David Bailey with Macquarie. Your line is open.

Good morning guys. Just in relation to US masks and accessories, you've talked to adherents and resupply as key drivers of growth. Just wondering if you can comment on your views as to those factors being drivers of growth over the next two to three years?

Yeah, that's a good question, David. I'll hand that to Rob. Yep, thanks David. Yep, the resupply program has definitely supported the mask portfolio. We've talked many times, you've got to understand the feedback of this. If you can get patients onto a good mask, they're more likely to stay on treatment, they'll do better, and then they'll need a mask. And so we continue to see that dynamic happening. Our software solutions that support the resupply programs and enable our HME customers to manage resupply programs more efficiently and ensure that the patients have the treatment that they need when they need it are also supporting it. These are long-term programs. We've been running resupply programs for many years now, and our teams will continue to refine and focus it. As Mick said earlier though, these markets are competitive. We do have competitors playing it. We have competition in resupply programs as well as in mask, and it really gets down to we've got a really strong team executing broadly across all parts of the portfolio on this that will continue to make sure that we're providing the best solutions for patients and providers delivering the best outcomes. So I think it's really as steady as she goes progress. We really like these resupply programs and they're providing us a very solid, steady business.

Thanks very much.

Next question is from Sean Lemon with Morgan Stanley. Your line is open.

Good morning everybody. Mick, I wonder if we get a little bit more granularity on the Novartis study you mentioned in your preliminary comments and perhaps some timelines that would be really useful.

Yeah, thanks for the question Sean. I wasn't at ERS, but I'll hand over to Dave Vendavis who can give us some more detail on the Novartis clinical trial. Terrific,

Sean. We mentioned in the opening remarks it goes by the name of MAGNIFI, and of course with trials these days you have to have a good acronym, and that stands for Maximizing Adherence and Gaining New Information for Your COPD. The trial is going to be, it's obviously sponsored by Novartis, and what it's doing is taking patients within clinics and then within those clinics randomizing the patients to either standard clinical practice or using Propeller. And then there'll be a comparison, and the endpoint is the time to failure of treatment. And then failure of treatment is defined in various ways such as needing additional medication, having some particularly acute exacerbations, lining up in hospital, those kinds of things. And it'll look and see whether or not adding the adherence benefits of Propeller lengthens the time that patients stay in that good controlled state. It's beginning recruiting now, and I believe it's supposed to run through the end of 2021. So it will take quite a while before it meets the end of that time period. But the important thing is a lot of the data that's been out now has been done in the asthma setting. Obviously that's an important area. We want to take care of those patients, but the COPD strategy is very important to us because of the way it connects with our overall respiratory care strategy. So having someone like Novartis sponsor a study looking at Propeller benefits to a COPD patient population, we think is a real important milestone, and we'll look for good benefits to come out of that study in the future. But it will be a few years.

Fantastic. Thanks, Dave. Thanks, Nick. Thanks, Sean.

Your next question comes from Anthony at the drone with Jeffreys. Your line is open.

Thank you, Gray. I'm just going to have a follow up to the Novartis question somewhat. Nick, you mentioned a couple of weeks ago indications of interest from AstraZeneca, Glaxo, and Novartis on Propeller Health. I'm just wondering if you have an update there and anything you can share potentially on how that would be priced on a per user per month basis. Thanks.

Yeah, thanks for the question, Anthony. You know, pharma companies, there are many respiratory pharmaceutical pharma players in the field, and the names you mentioned all have drugs in the market. One thing about pharma companies is they're very competitive with each other, and they don't want to share information shared too much publicly. Certainly, you know, on our Investa Deck, we put the names of those where we have published clinical data with and we're working with, and the reason we're bringing Novartis, you know, in our prep remarks here is that's a public clinical trial. One of the interesting things that's happening here is there's a lot of trials that aren't public that are happening out there that obviously we cannot talk about. As we look forward, the important thing, if you think about milestones, Anthony, to sort of look at on this sort of digital health option play, if you like, that we have in our strategy with the Propeller solution is when somebody goes from these pilot trials to a commercial trial and when they would allow us to talk about that publicly. And so if and when that happens, that's the milestone I think that's most important, you know, in a material element to our shareholders. As I said in the prep remarks, you know, we got in early with Propeller and this is a long road. I think I use the analogy that it's an ultra marathon. You know, this is beyond just 26.2 miles. This is a huge journey. COPD number two cause for hospitalisation and re-hospitalisation, the number three cause of death. This has such good runway for us in the future, but there's nothing material in the quarter and so we're just giving the update. We hit 100,000 patients. We think that's fantastic. It's great validation to have Nevada start this public study. It's going to take a couple of years as Dave said, that I would expect that before those couple of years we'll have some other milestones of going to some commercial trials that we can talk about, you know, in upcoming conference calls. But right at the moment, this quarter, Anthony, there's nothing to report other than really good early data. Thank you.

Your next question comes from Sol Hadassin with UBS. Your line is open.

Thanks. Good morning, Mick. Good morning. Well, good afternoon, Mick and Brett. Can I just ask about the SAS business, Mick, and the tie-up with Cerner. I mean, it suggests that Cerner are effectively leaving that post-acute space to providers like yourself. I'm just interested to know how much work needs to be done to allow the two architectures to talk to each other. If you have an electronic medical record, for example, in the acute space offered by Cerner, what work has to be done in terms of your SAS business to allow those two systems to talk to each other? When do you expect to see the ability of the benefits of that tie-up to come through?

Yeah, thanks for the question, Sol. It allows us to talk to the area of interoperability, which is incredibly important for us here at ResMed. We have 100 API calls per second from integrators into our air solutions ecosystem. So every second, 100 interactions with another EHR, EMR, whether it's an individual person on their MyAir app checking their therapy or a physician at Massachusetts Eye and Ear looking over 20,000 patients to do some management by exception protocol. And so the Cerner contract or deal is that they, Cerner are looking for ResMed and really truly through our MatrixCare managed team to take care of home health and hospice customers for them. So they have customers that have hospital systems, but for the out of hospital part where it goes to home health and hospice, they want ResMed to be their partner to take care of those. And we think it's a really exciting opportunity for the MatrixCare sales team and for the Cerner sales team to partner up and have that move forward. And it was really interesting at the Cerner conference to have our MatrixCare and Brightree teams there and all the technology available from the iPad app and all the capabilities that we have for home health and hospice and to get some really good leads. It's not going to be material in the future. What we're talking about is that idea of interoperability with Cerner, with Epic, with all scripts, with all the players in hospital healthcare. We think it's going to be really important that ResMed is the best person that can provide that handshake, that API from someone in acute care to what they call post-acute care, but what we call out of hospital healthcare. And we think that partnership is going to be really strong. So we'll give you updates as the progress not just to the Cerner home health and hospice partnership, but to other partnerships with hospital systems, hospital providers and EHR providers. We think it's a good milestone to show that one of the top three leaders along with Epic and all scripts there in hospital EHR has chosen ResMed as their home health and hospice care provider with our MatrixCare managed solution. And we're really excited about that.

Thanks. Your next question is from Thomas Heal with Goldman Sachs. Your line is open.

Hi there Chris Cooper on the phone. Apologies if I missed it, but I didn't hear much commentary on MOBI or portable oxygen concentrates this morning in your prepared remarks. Could you just give us an update there please?

Yeah thanks for the question Chris. I'll

hand that to Rob.

Thanks

Nick. Yes Thomas. We as you recall we launched MOBI very early this year and we've sort of been in a really still in a learning mode. It's a great product. We're actually learning a lot about the performance of the product and we've talked about and continue to validate the issue of the balance of the performance specifications and how the product works. And so we're in good shape there. What we're also learning is that it is challenging through particularly through the US reimbursement model is how to get the right patients on the right treatment and how to get that properly funded. And we have been trialling experiments in looking at ways to optimize and develop that. Really we're learning a lot about what our sort of future pathways to market would be and how can we make it best suitable for our HME customers to support patients. And also what are the future needs of products further down the track and feeding learnings into our future roadmap. So with that all going on the learning process is quite successful. We're still not a major market share player with the product and that's unlikely to change into the short-term future with the MOBI product because we currently are investing in it and the way we're heading at the moment.

Your next question is from Mike Mattson with Needed Med Company. Your line is open.

Hi. Thanks for taking my question. I guess I just wanted to ask about there's a I guess a bill in Congress, HR 2771, to kind of extend the rural relief from the bidding program that I think is set to expire at the end of 2020. So just curious to get your thoughts on that and what that would if that were not to be successful. Thanks.

I'll hand that question to Dave Pindales.

Thanks Mike. You know there's a lot of efforts underway in the U.S. Congress right now to try to provide relief particularly the one you mentioned which is to try to extend the relief that was given that was that sort of 50-50 blend between prior reimbursement and the new system reimbursement into those rural areas. We certainly support that legislation. We think it's important that our customers who are operating particularly in extended areas where they've got to drive many miles to a patient's homes need to have reimbursement that reflects the operating costs that they've got and we would certainly hope that the champions that are there in Congress will carry the day. Now you know as your question implies there's a lot going on in the U.S. Congress these days. It's very difficult to predict whether something like that will ultimately pass or whether CMS could respond on their own and provide that kind of relief. If it doesn't, I think as I said before when talking about competitive bidding, you know we'll obviously work with our customers to do what we can to support them. We think the remote capabilities of our devices you know are ideal for providing care in a remote setting. You could do things like change some of the settings on a CPAP. You can certainly interrogate the CPAP for information about the quality of the therapy that's been provided all without having to drive to someone's home. So we think that those systems and helping customers whether they're in rural areas or not to deploy them is probably the best thing we can do to help in that kind of a setting. But we'll continue to support that legislation and other efforts with CMS to try to make sure that the Medicare you know policies and reimbursement is as favorable as it can be for the ultimate benefit of Medicare beneficiaries.

Great, thank you.

Your next question is from Shane Storey with Wilson. Your line is open.

Yeah morning. Thanks for taking my question. It's maybe a bit tangential but it relates to the CMS reimbursement changes that hit skilled nursing providers this month. Sort of weighing up that as an incremental opportunity for Matrix. I mean do you have an estimate of the proportion of providers that are yet to adopt good solutions there? I'm just interested to know just how much growth there is scope sort of towards available for Matrix there in the SAS market.

Yeah Shane, thanks for the question. It's a good one. You know there are changes in reimbursement not just in HME as we just talked about but also in skilled nursing facilities and within home health and hospice. These provide excellent opportunities for software as a service providers to if you're ahead of the game as Matrix Care was for the skilled nursing facilities changes and as we are for the home health and hospice changes to be able to support customers through that change and even grow share because you've got the best solution that deals with those changes well. You know one thing I can say is that the new CEO there at Matrix Care Steve Pachico has great relationships with the customers and he has a great sales team that know the skilled nursing facility teams really well and we've not only helped them through these changes in this quarter but also set them up for success that our systems are operating well under the new reimbursement approach within those verticals. So you know that's a really when you roll that all together it's part of sort of that 2020 execution plan I talked about earlier that we see a good path even if the blended rate of growth across these seven out of hospital health care verticals is in those high single digits we think there are areas where we can get better growth than that and we plan to exit 2020 with a double digit growth trajectory in the segment of SAS and part of that is going to be doing just what your question asked about which is every part of the vertical whether it's skilled nursing facilities whether it's our new play in home health and hospice the hunting license with Cerner in addition to our ability to grow share through having solutions that are ahead of the curve on reimbursement changes they're all opportunities to be able to grow faster and get you know form longer partnerships with our customers. Thanks Mick, appreciate it.

Your next question is from Steve Ween with Ebbins, your line is open.

Oh hi sorry just wanted to come back to Brett on the gross margin. You typically give a bit of a range for that in terms of guidance. Are you able to do that again this quarter?

Yeah sure Steve, there's a lot of moving parts but I would think it'd be broadly consistent with where we were for Q1.

Perfect, thank you.

Thanks

Dave.

And your next question is from Anthony Patrone with Jefferies, your line is open.

Hey just a quick follow-up on masks. I know you mentioned Mick a couple of launches. I'm just wondering you know how much stocking potentially there was in a quarter and then just on on lead item you know is there any Dave you mentioned you know we spoke a couple days ago but is there any indication on how this is you know kind of coming in post the notification period? Thanks again.

Yeah so Anthony I'll take the first party question on masks and Dave will take the second part. Yeah clearly we had excellent you know new product introduction over the last 12 months but our you know your question is around do people do stocking orders? Our US distribution and frankly our global distribution partners are getting very intelligent about inventory management you know not just those who use Brightree and have ResMed's Brightree inventory management system which will actually manage it for them but many of them are getting really appropriate on that knowing when a new mask comes watching how their RTs are setting it up and seeing the patient flow and making sure they don't get too ahead of the curve or behind the curve. You don't want a patient in the fitting room that wants the N30 and it's not there but on the other hand you don't want excess inventory because they have inventory carrying costs as everyone knows and our US distributors are actually quite sophisticated on this so I you know obviously when some you know you launch a brand new mask people do need to make sure they've got that mask on the shelf

but

given the proportion of existing resupply patients which is a very large portion particularly of US distributors patient flow we don't think there was you know material impact from from stocking. Now we don't have full insight into our customers that aren't using you know Brightree or other inventory management solutions but we think it's a pretty steady approach and we've done new product introductions you know over the 20-30 years we've been in business and I don't we haven't seen that at a significant rate before and I don't think we saw any significant rate of that during the last quarter. Dave the second public question for you.

Sure yeah thanks Anthony I mentioned a little bit earlier that ResMed along with other industry participants put a lot of energy and resources behind trying to educate the market participants who are going to be bidding about various factors including lead item pricing and we developed a calculator that was that was put out there were some stats that were just discussed in the med trade meeting just earlier this week in Atlanta that there were you know over 17,000 downloads of that calculator and that's simply the one that was available through the the participants here CMS had their own calculator that folks no doubt downloaded from the conversations that I've had my understanding is that most DME's have a pretty good understanding of lead item pricing and how it works and hopefully they've availed themselves of the tools to be able to model out scenarios based on their own business and their own volume of products in different categories so that they can bid you know intelligently and in a way that's going to ultimately derive you know a fair and reasonable reimbursement so you know I'm confident that we we got that message out that it was received obviously we don't know how people bid and we'll work with customers as best we can to try to implement things when when the day comes but we're confident that we did what we could to try to educate. Thanks again.

We are now at the one hour mark so I will turn the call back over to Mick Farrell.

Thanks Chris and thanks again to all our shareholders for joining us on the call this quarter. I'd also like to thank the 7,500 res medians many of whom are also shareholders for their dedication and hard work helping people breathe better sleep better and live better lives outside the hospital in 120 countries worldwide. Thanks for all that you do today and every day. We'll talk again with our shareholders in approximately 90 days. Talk to you all then.

Great thank you all again for joining us today. If you do have any additional questions please don't hesitate to reach out to investor relations or to me directly. As previously mentioned all documents including the transcript and a replay of today's call will be available on our website later today. Chris you may now close the call.

Ladies and gentlemen this does conclude today's conference call. Thank you for participation in Jimmy now disconnect.